Healthcare >> CEO Interviews >> February 2, 2002
WILLIAM C. DOW is President and Chief Executive Officer of Aksys, Ltd.
He joined the company in October 1999. Since that time, he has directed
the company through the clinical trial for the Aksys Personal
Hemodialysis System (PHD'), obtained FDA approval to market the product,
raised over $100 million in additional capital for the company, and
restructured the organization for commercialization. Before joining
Aksys, he was President and CEO of PLC Systems, a pioneer in the
development of products used to perform transmyocardial
revascularization (TMR), a medical treatment for patients suffering from
coronary artery disease. Prior to PLC, he served as President and CEO of
Deknatel Snowden Pencer, a medical device manufacturer of surgical
products, which was acquired in July 1996 by Genzyme, a Cambridge,
Massachusetts-based biotechnology company. Mr. Dow joined Deknatel in
1993 and led a turnaround that produced a sales growth of over 20% and a
doubling of operating profits. He has almost 30 years of experience in
the medical device industry, having held various positions in sales,
marketing, distribution and general management with such companies as
American Hospital Supply, Terumo, and Kendall. Mr. Dow is a graduate of
the United States Naval Academy. Profile
Mr. Dow: Aksys was founded in the late 1980s by Rod Kenley. Rod had been
talking with a number of nephrologists about the concept of
